We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
LCT granted E.U. Patent for Tissue Engineering
News

LCT granted E.U. Patent for Tissue Engineering

LCT granted E.U. Patent for Tissue Engineering
News

LCT granted E.U. Patent for Tissue Engineering

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "LCT granted E.U. Patent for Tissue Engineering"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Professor Bob Elliott, LCT's Medical Director said, "Whilst we have successfully taken single cell animal transplant treatments into the clinic, a number of chronic disease states could benefit from transplantation of a mix of cells or artificial tissue that work together to ensure survival and appropriate function."

The patent will be assigned to Diatranz Otsuka Limited (DOL), a joint venture company established by LCT and Otsuka Pharmaceutical Factory, Inc. to commercialise xenotransplantation for the treatment of Type 1 diabetes. LCT has a 50 per cent shareholding in DOL, and a service agreement to supply research and development and administrative services to the joint venture. Under the Services and Products agreement, DOL will supply pig cells to LCT for use in developing new xenotransplantation treatments in non-diabetes related disease areas, including neurodegenerative disorders.

Dr Andrea Grant, LCT's CEO, said, "This patent adds to a still growing portfolio of intellectual property and protects future product development opportunities in a range of chronic diseases, particularly those requiring transplantation of a mix of cells or artificially engineered tissues. This patent award means we are well poised to take full advantage of developments in the fields of cell and tissue engineering in our animal transplantation platform."

Advertisement